Inactive Instrument

Caplin Point Laboratories Ltd Stock NSE India S.E.

Equities

INE475E01018

Pharmaceuticals

End-of-day quote NSE India S.E.
- INR - Intraday chart for Caplin Point Laboratories Ltd
Sales 2024 * 16.92B 203M Sales 2025 * 19.11B 229M Capitalization 103B 1.23B
Net income 2024 * 4.57B 54.82M Net income 2025 * 4.17B 50.04M EV / Sales 2024 * 6.06 x
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 5.37 x
P/E ratio 2024 *
22.6 x
P/E ratio 2025 *
20.9 x
Employees -
Yield 2024 *
0.23%
Yield 2025 *
0.25%
Free-Float 25.33%
More Fundamentals * Assessed data
Caplin Point Arm Gets US FDA Final Nod for Ofloxacin Ophthalmic Solution MT
Caplin Point Unit Receives US FDA Nod for Eye Treatment Medication MT
Caplin Steriles Limited, A Subsidiary of Caplin Point Laboratories Limited Gets USFDA Approval for Ketorolac Tromethamine Ophthalmic Solution CI
Caplin Point Laboratories Arm Starts Operations of Oncology Facility at Kakkalur, India MT
Caplin One Labs Limited, a Wholly Owned Subsidiary of Caplin Point Laboratories Limited Successfully Completes New Oncology (Anti-Cancer) Facility, Commences Operations CI
Transcript : Caplin Point Laboratories Limited, Q3 2024 Earnings Call, Feb 09, 2024
Caplin Point Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Caplin Point Laboratories to Invest INR7 Billion in Tamil Nadu, India MT
Caplin Point Unit Gets US FDA Final Approval for Generic Ear Infection Drug MT
Caplin Point Laboratories Limited Announces Resignation of Hero Velladurai as President, R&D CI
Transcript : Caplin Point Laboratories Limited, H1 2024 Earnings Call, Nov 09, 2023
Caplin Point Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
Caplin Point Unit's Injectable and Ophthalmic Plant in India Gets VAI Classification from US FDA MT
Transcript : Caplin Point Laboratories Limited, Q1 2024 Earnings Call, Aug 08, 2023
Caplin Point Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2023 CI
More news
Managers TitleAgeSince
Chief Executive Officer 69 15-03-27
Director of Finance/CFO - 16-02-18
Chief Administrative Officer - -
Members of the board TitleAgeSince
Chairman 71 -
Chief Operating Officer - 10-11-30
Chief Executive Officer 69 15-03-27
More insiders
Caplin Point Laboratories Limited is an India-based pharmaceutical company. The Company is engaged in producing, developing, and marketing a range of generic formulations and branded products and exporting to overseas markets. Its products include tablets, dry syrups (bottles), soft gels, capsules, suppositories, liquid syrups (bottles), liquid injectables in ampoules and vials, lyophilized vials, prefilled syringes (PFS), emulsion injection in ampoules and vials, ophthalmic droppers, pre-mix bags, topicals and sachets (liquids and powders). It also manufactures a range of ointments, creams, gels and lotions. Its principal research and development facilities are in Tamil Nadu, India. Its principal manufacturing facility is in Puducherry, India. It has presence in Latin America (LATAM), Southern Africa and Francophone Africa along with a presence in United States of America and European region. The Company’s subsidiaries include Caplin Point Far East Limited and Caplin Steriles Limited.
More about the company